AAD "hopeful" for sunscreen rule
This article was originally published in The Rose Sheet
Executive Summary
The American Academy of Dermatology says it "does not have any specific knowledge about a release date for the sunscreen monograph" but "is hopeful that the FDA will release the sunscreen monograph as soon as possible," noting that in September FDA indicated that it aimed to publish its long-awaited final rule by the year's end. The academy announced Dec. 3 that it is closing down its "Seal of Recognition" program for sunscreens of demonstrated excellence, confident that FDA's updated guidelines are imminent (1"The Rose Sheet" Dec. 7, 2009). "The board did [also] consider the fact that given its low participation levels, the AAD seal program was not meeting its public education goals, which [were] to encourage greater use of more protective sunscreens and increase public awareness of the dangers of excessive sun exposure," AAD President David M. Pariser told "The Rose Sheet" Dec. 4. He noted that the costs associated with the seal program exceeded the revenue it generated, so it contributed no funds to the academy's awareness activities and therefore will not be missed on that count. Through its outreach initiatives, AAD has enabled its members to conduct 1.9 million free skin cancer screenings, detecting more than 188,000 suspicious lesions, including more than 21,500 suspected melanomas
You may also be interested in...
Dermatologists Expect FDA Sunscreen Rule "Soon," End Product Seal Program
The American Academy of Dermatology says its seal of approval for products offering sun protection is no longer necessary with FDA's final sunscreen rule imminent
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.